Compare YSXT & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | RPID |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 34.7M |
| IPO Year | 2023 | 2021 |
| Metric | YSXT | RPID |
|---|---|---|
| Price | $1.38 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 3.0K | ★ 151.4K |
| Earning Date | 07-10-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,587,000.00 |
| Revenue This Year | N/A | $16.95 |
| Revenue Next Year | N/A | $17.92 |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $0.50 | $0.58 |
| 52 Week High | $2.58 | $4.94 |
| Indicator | YSXT | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 44.29 |
| Support Level | $1.21 | $0.58 |
| Resistance Level | $1.31 | $2.18 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 39.18 | 66.24 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services, and Software Development and Information Technology Services. Key revenue is generated from the Auto Insurance Aftermarket Value-added Services segment, which includes four types of value-added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services, and vehicle maintenance and other value-added services.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.